Psychiatric manifestations of Anti-NMDA receptor encephalitis in a man without tumor

Psychosomatics

Volumn 52, Issue 1, 2011, Pages 13-

  Kung, Doris Hichi ^a   Qiu, Cuie ^a   Kass, Joseph Shimon ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; RITUXIMAB;

ADULT; AGGRESSION; AGITATION; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DYSKINESIA; ELECTROENCEPHALOGRAM; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOTHERAPY; MALE; MANIC PSYCHOSIS; NEUROLEPTIC MALIGNANT SYNDROME; PARANOIA; PSYCHOSIS;

EID: 84859728041     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2010.11.010     Document Type: Article

References (13)

1. Sansing LH, Tüzün E, Ko MW, et al: A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007; 3:291-296
2. Dalmau J, Gleichman AJ, Hughes EG, et al: Anti-NMDAreceptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091-1098
3. Picard LS, Lindsay S, Strawn JR, et al: Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 28:530-535
4. Iizuka T, Sakai F, Ide T, et al: Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008; 70:504-511
5. Tuzun E, Dalmau J: Limbic encephalitis and variants: classification, diagnosis and treatment. The Neurologist 2007; 12:261-271
6. Dalmau J, Tüzün E, Wu HY, et al: Paraneoplastic anti-Nmethyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61:25-36
7. Farver DK: Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003; 2:21-35
8. Strawn JR, Keck PE Jr, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870-876
9. Ishiura H, Matsuda S, Higashihara M, et al: Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology 2008; 71:1921-1923
10. Gürcan HM, Keskin DB, Stern JN, et al: A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9:10-25
11. Shams'ili S, de Beukelaar J, Gratama JW, et al: An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253:16-20
12. Ahmed AR, Spigelman Z, Cavacini LA, et al: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355:1772-1779
13. Pels H, Schulz H, Manzke O, et al: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002; 59:213-216